Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AltimmuneALT -1.50%32 3-Year EPS without NRI Growth Rate is 17.90% as of Jun. 2026, which is 28% below its 10-year median of 24.90. GuruFocus rates ALT with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,160 Biotechnology companies, Altimmune ranks better than 52.07% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 17.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 12.80% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 28.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Altimmune was 69.40% per year. The lowest was -5.90% per year. And the median was 24.90% per year.
Altimmune (NAS:ALT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Altimmune 3-Year EPS without NRI Growth Rate Related Terms
ALT vs ARVN, AUTL, EIKN: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Altimmune's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Altimmune 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Altimmune's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Altimmune's 3-Year EPS without NRI Growth Rate falls into.
Altimmune 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 17.90% mean?
Altimmune (ALT) has a 3-Year EPS without NRI Growth Rate of 17.90% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Altimmune and its competitors. This is 28% below median its historical median of 24.90. According to the industry distribution chart, Altimmune ranks #556 out of 1160 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Altimmune's 3-Year EPS without NRI Growth Rate too high?
Altimmune's current 3-Year EPS without NRI Growth Rate of 17.90% is 28% below median its 10-year median of 24.90. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 15.95. Altimmune's value of 17.90% is 12.2% above this industry median. Based on the distribution chart, Altimmune ranks #556 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Altimmune has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Altimmune's 3-Year EPS without NRI Growth Rate compare to ARVN and AUTL?
According to the Biotechnology industry distribution chart, Altimmune ranks #556 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Altimmune in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 15.95. Altimmune's value of 17.90% is 12.2% above this benchmark. While the company's 10-year median is 24.90 vs. the industry median of 15.95, Altimmune has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 15.95, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Altimmune's current 3-Year EPS without NRI Growth Rate of 17.90% is 12.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Altimmune and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 15.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Altimmune's current 3-Year EPS without NRI Growth Rate is 17.90%, which is 28% below median its own 10-year median of 24.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Altimmune (ALT) has a current 3-Year EPS without NRI Growth Rate of 17.90%. The current 3-Year EPS without NRI Growth Rate is 17.90%, which is 28% below median its 10-year median of 24.90 and 12.2% above the Biotechnology industry median of 15.95. Altimmune's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Altimmune (ALT), the current 3-Year EPS without NRI Growth Rate is 17.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
32GF Score
Get the complete analysis for ALT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALT has been successfully added to your 
